TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT00858975

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: cryotherapy
Description: Placing 4-6 cryotherapy probes into the renal tumors and conducting two cycles of freezing and thawing
Study: NCT01752998

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Treating Opioid Patients' Pain and Sadness (TOPPS)

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Health Education
Study: NCT01296620

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ulimorelin Intravenously (IV)
Description: 160 µg/kg daily (QD)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ulimorelin Invtravenously (IV)
Description: 480 µg/kg daily (QD)
Study: NCT02201329

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Azacitidine
Description: Azacitidine (subcutaneous)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Volasertib
Description: Volasertib escalating doses (intravenous)
Study: NCT01296620

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: 5% dextrose in water
Description: Placebo
Study: NCT01615185

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: full-dose amisulpride
Description: amisulpride 800mg/d

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: full-dose amisulpride
Description: amisulpride 800mg/d
Study: NCT00586001

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Unified Protocol for Transdiagnostic Treatment of Emotional Disorders
Description: Cognitive-behavioral treatment in development for emotional disorders
Study: NCT04152161

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: BCG vaccine SSI
Description: Participants will receive a single 0.1 milliliter (mL) volume of BCG vaccine SSI, administered intradermally in deltoid region of the upper arm.

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Participants will receive a single 0.1 mL volume of normal saline, administered intradermally in deltoid region of the upper arm.
Study: NCT04080401

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Game-based rehabilitation exercise
Description: 4 games (exercises) on operated limb, for 3 sessions daily, until outpatient physiotherapy review visit.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Conventional brochures of rehabilitation exercise
Description: 4 exercises on operated limb, 30 reps each, for 3 sessions daily, until outpatient physiotherapy review visit.
Study: NCT03168854

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Genetically-attenuated p52-/p36-/sap1- Plasmodium falciparum parasite (GAP3KO) strain
Description: Genetically attenuated parasite created by triple deletion (GAP3KO) by deleting the P52, P36, and SAP1 genes in the NF54 wild-type (WT) strain of Plasmodium falciparum (Pf p52(-)/p36(-)/sap1(-) GAP).
Study: NCT03059511

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nalbuphine
Description: Opioid Pain Medicine

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nalbuphine
Description: Opioid Pain Medicine
Study: NCT00430027

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Capecitabine
Description: Given 650 mg/m\^2 BID on days of ration therapy, 825 mg/m\^2 day 1-14, day 15-20 off x 4

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxaliplatin
Description: Oxaliplatin 30 mg/m\^2, 130mg/m2 IV Q 21 days x 4

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cetuximab
Description: Initial Cetuximab 400 mg/m\^2 IV starting no earlier than 8 weeks and no later than 10 weeks after surgical resection
Study: NCT03168854

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Genetically-attenuated p52-/p36-/sap1- Plasmodium falciparum parasite (GAP3KO) strain
Description: Genetically attenuated parasite created by triple deletion (GAP3KO) by deleting the P52, P36, and SAP1 genes in the NF54 wild-type (WT) strain of Plasmodium falciparum (Pf p52(-)/p36(-)/sap1(-) GAP).

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Malaria challenge
Description: Exposure to mosquitoes infected with P. falciparum.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Malaria challenge
Description: Exposure to mosquitoes infected with P. falciparum.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Malaria challenge
Description: Exposure to mosquitoes infected with P. falciparum.
Study: NCT02530593

Intervention type: BEHAVIORAL
Intervention: There is no intervention, only observation
Study: NCT04350918

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Muscle Enery Techniques
Description: Group of patients that underwent muscle energy technique as a mean of treatment for the complaint

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Static Stretching
Description: Set of patients that had static stretching technique for the treatment for the complaint
Study: NCT02516345

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Fitbit
Description: Fitbit devices are wireless pedometers that track the steps of participants, and will be offered in conjunction with a tailored website with customized information for participants.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Fitbit
Description: Fitbit devices are wireless pedometers that track the steps of participants, and will be offered in conjunction with a tailored website with customized information for participants.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Incentives
Description: Incentives will be awarded to participating children for meeting step targets as measured by the Fitbit pedometer.
Study: NCT00005792

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: etoposide phosphate
Description: Etoposide phosphate 1363 mg/m\^2/day IV over 4 hours (total dose 2726 mg/m\^2, or 2400 mg/m\^2 etoposide equivalents), beginning 24 hours after the completion of the last infusion of topotecan Days -4, -3

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: melphalan
Description: Melphalan 50 mg/m\^2/day IV over 30 minutes (total dose 150 mg/m\^2), followed immediately by topotecan. Days -7, -6, -5

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: topotecan
Description: Topotecan 3.3 mg/m\^2/day (starting total dose = 10 mg/m\^2 for level 2) IV over 30 minutes. No topotecan will be administered on the first dose level Days -7, -6, -5

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Autologous Stem Cell Rescue
Description: reinfusion of stem cells, Day 0
Study: NCT03422744

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: trans bronchial biopsy guided by echo-endoscopic miniprobes
Description: We get a sample trough transbronchial biopsy guided by echo-endoscopic miniprobe.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: if first one negative: samples under fluoroscopic control
Description: If no diagnosis with first intervention we get a second sample by cytological smear, fine needle biopsy and transbronchial biopsy under fluoroscopic control
Study: NCT01970735

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Blood test
Study: NCT00003282

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: EF5
Description: Given IV

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: therapeutic conventional surgery
Description: Undergo resection

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: biopsy
Description: Undergo biopsy

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: pharmacological study
Description: Correlative studies
Study: NCT04609215

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: ALECSAT
Description: Patients will receive concurrent chemotherapy with carboplatin/gemcitabine with cycles repeated every 3 weeks.~During the loading phase, patients will receive ALECSAT at 28 days intervals at weeks 5, 9, and 13. Hereafter (the maintenance phase), ALECSAT will be administered every 12 weeks until disease progression, death, unacceptable toxicity, investigator/patient decision or EOT visit at 18 months.
Study: NCT02516345

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Incentives
Description: Incentives will be awarded to participating children for meeting step targets as measured by the Fitbit pedometer.
Study: NCT03949374

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: CRESTOR, reference formulation of rosuvastatin
Description: Use of ROVASRO for hypercholesterolemia

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ROVASRO, generic formulation of rosuvastatin
Description: Use of CRESTOR for hypercholesterolemia
Study: NCT04483271

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: 300 mg of omega3-FA
Description: The participant will receive 1,000 mg of wild salmon and fish oil complex once daily, which contains 300 mg of omega3-FA.~Baseline and follow-up serum levels of IL-1,IL-6, and TNF will be measured.
Study: NCT00622245

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lu AA34893
Description: per oral doses, divided in twice daily administrations as capsules, during 12 weeks, followed by a one-week tapering period

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lu AA34893
Description: per oral doses, divided in twice daily administrations as capsules, during 12 weeks, followed by a one-week tapering period

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lu AA34893
Description: per oral doses, divided in twice daily administrations as capsules, during 12 weeks, followed by a one-week tapering period

Intervention type: DRUG
Group type: OTHER
Intervention: Quetiapine fumarate
Description: per oral, once daily, during 12 weeks, followed by a one-week tapering period

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: per oral doses, twice daily as capsules during 13 weeks
Study: NCT02536196

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Embolic Protection Device
Description: Embolic protection

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Transcatheter aortic valve implantation (TAVI)
Description: Transcatheter aortic valve implantation (TAVI)

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Transcatheter aortic valve implantation (TAVI)
Description: Transcatheter aortic valve implantation (TAVI)
Study: NCT02031354

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Lysine Chloride
Description: Administration of 21g of lysine chloride (7g three times daily) for a period of time of 3 days
Study: NCT04481932

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trastuzumab combined with Pyrotinib and chemotherapy
Description: Pyrotinib is a small molecule, irreversible tyrosine kinase inhibitor with targets of epidermal growth factor receptor 1 (EGFR/HER1/ErbB1), human epidermal factor receptor 2 (HER2/ErbB2/Neu) and human epidermis Factor Receptor 4 (HER4/ErbB4).~As a new generation of anti-HER2 therapeutic targeted drugs, pirotinib covalently binds to the ATP binding sites of the kinase regions of EGFR, HER2 and HER4 in cells to prevent homogeneity and heterogeneity of EGFR, HER2 and HER4 in tumor cells Dimer formation, inhibiting its own phosphorylation, blocking the activation of downstream signaling pathways, thereby inhibiting tumor cell growth
Study: NCT01211002

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: radiotherapy combined with EP
Description: Tumor vo lume is 60-66 Gy / 30-33f and the combination regimen is etoposide (50 mg/m2 day1-5, 29-33) and cisplatin (50 mg/m2 day1, 8, 29, 36) in the 1st, 4th weeks of radiotherapy for 2 courses.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: radiotherapy / EP combined with recombinant human endostatin
Description: Anti-vascular targeting therapy The number of courses is 3 \~ 4 and each course last for 28 days. Recombinant human endostatin（Endostar）：15mg，d1-14, intravenous injection.
Study: NCT03370601

Intervention type: DRUG
Group type: OTHER
Intervention: Infliximab
Description: Infliximab 10mg/kg every 8 weeks

Intervention type: DRUG
Group type: OTHER
Intervention: Mercaptopurine
Description: 6-mercaptopurine 1 à 1,5 mg/kg

Intervention type: DRUG
Group type: OTHER
Intervention: Azathioprine
Description: Azathioprine 2 à 2.5mg/kg/j

Intervention type: DRUG
Group type: OTHER
Intervention: Infliximab
Description: Infliximab 5mg/kg every 8 weeks
Study: NCT03782792

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Spesolimab
Description: Solution for infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Solution for infusion
Study: NCT00645060

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: high performance liquid chromatography
Description: Performed on serial blood samples from 0 to 168 hours and daily X5 days 24 hour urine samples

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: pharmacological study
Description: Serial blood samples from 0 to 168 hours and daily X5 days 24 hour urine samples

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: radionuclide imaging
Description: 1-3 hours, 1 day, 2 days, 3-5 days and 6-7 days post Y-90 anti-CEA antibody infusion

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: single photon emission computed tomography
Description: 2 days and 3-5 days post antibody infusion

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: yttrium Y 90 DOTA anti-CEA monoclonal antibody M5A
Description: Dose escalation from 12 mCi/m2 through 18 mCi/m2 increasing by 2 mCi/m2 with each escalation
Study: NCT01927874

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Infiltration
Description: injection of local anesthetic, associated with general anesthesia

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Spinal block
Description: injection of anesthetic

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bupivacaine
Description: 10ml 0.5% bupivacaine.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 10 mg of hyperbaric 0.5% bupivacaine
Description: Spinal punction and injection of local anesthetic
Study: NCT01280175

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: charcoal block

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Aerochamber Plus spacer

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: pMDI standard actuator
Study: NCT04446494

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Identification and preservation of arm lymphatics (DEPART)
Description: Indocyanine green was utilized to identify arm sentinel nodes, and 0.1 ml MB was injected into the arm sentinel nodes to reveal the subsequent-echelon nodes and lymphatics. Gross arm lymph nodes were examined by intraoperative partial frozen section and were removed if positive.
Study: NCT02187133

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carfilzomib
Description: Given IV; Dose Level (DL)~Twice Weekly:~DL -1 and DL 1: 15 mg/m\^2~Weekly:~DL 1.5: 20,27,27 mg/m\^2, DL 2: 20,36,36 mg/m\^2, DL 3: 20,56,56 mg/m\^2 DL 4: 20,70,70 mg/m\^2

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bendamustine
Description: Given IV; Dose Level (DL)~DL -1: 75 mg/m\^2 DL 1,1.5, 2, 3, and 4: 90 mg/m\^2
Study: NCT01678911

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Gralise
Description: Subjects will start at 600mg and titrate up by 600mg a week for two weeks (to 1800mg), then remain on 1800mg steady state dose of medication (or placebo pills) for 2 weeks. If intolerable side effects occur, the dose may be reduced to last tolerable dose at the discretion of the PI. A 2-week down-titration will be used. Subjects will have 1 week of wash-out before repeating the above procedure for the other arm of the study (placebo or medication).
Study: NCT02187133

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: Given IV; 375 mg/m\^2
Study: NCT04358991

Intervention type: DRUG
Intervention: Ceftazidime-avibactam
Description: collection of blood samples around clinical dosing immediately pre-dose, then at the following times thereafter: 1, 2, 4, 6, 8, and 12 hours and EMR review.
Study: NCT02564562

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: [14C] PF-06463922
Description: Single oral dose of 100mg PF-06463922 + \[14C\] PF-06463922
Study: NCT00574366

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: erlotinib
Description: Levels:~* 1 Erlotinib 50 mg/d~* 2 Erlotinib 50 mg/d~  * 1 Erlotinib 100 mg/d~ * 2 Erlotinib 100 mg/d~ * 3 Erlotinib 150 mg/d~ * 4 Erlotinib 150 mg/d

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RAD001
Description: Levels~minus 1: RAD001 2.5 mg/d~minus 2: RAD001 2.5 every other day~1. RAD001 2.5 mg per day~2. RAD001 5 mg per day~3. RAD001 10 mg per day~4. RAD001 10 mg per day
Study: NCT02647892

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: lidocaine
Description: local anesthesia

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: lidocaine
Description: local anesthesia

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: lidocaine
Description: local anesthesia

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: lidocaine
Description: local anesthesia

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: sodium bicarbonate
Description: additional drug added to lidocaine

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: sodium bicarbonate
Description: additional drug added to lidocaine
Study: NCT01000805

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Participants received placebo QD, po for 8 weeks.
Study: NCT02910973

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Vagus Nerve Stimulation
Description: Patients will receive transcutaneous stimulation of the auricular branch of the left vagus nerve for 5 minutes. Blood will be withdrawn prior to stimulation and 1 hour following the stimulation. The device is a handheld electrical pulse generator and a pair of electrodes to be placed at the ear for stimulation. The specific target at the ear will be the auricular branch of the vagus nerve which innervates the skin of the ear canal. Electrodes will be placed near/at the entrance to the canal of the ear to provide stimulation to the auricular branch of the vagus nerve.
Study: NCT02647892

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: sodium bicarbonate
Description: additional drug added to lidocaine
Study: NCT01849562

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sovaprevir
Description: Nonstructural protein 3/4A protease inhibitor.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sovaprevir
Description: Nonstructural protein 3/4A protease inhibitor.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ACH-3102
Description: Nonstructural protein 5A inhibitor.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ACH-3102
Description: Nonstructural protein 5A inhibitor.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ribavirin

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ribavirin

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT02556580

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Albumin 20%
Description: Intervention: intravenious infusion Drug: albumin

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Albumin 20%
Description: Intervention: intravenious infusion Drug: albumin

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Albumin 20%
Description: Intervention: intravenious infusion Drug: albumin
Study: NCT04216667

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Catheter ablation
Description: Catheter ablation

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Catheter ablation
Description: Catheter ablation

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Catheter ablation
Description: Catheter ablation

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Catheter ablation
Description: Catheter ablation
Study: NCT04278716

Intervention type: OTHER
Intervention: Safe return to play checklist
Description: this objective checklist will be utilized by the physical therapy staff and surgeon to determine whether an athlete is safe to return to their sport
Study: NCT04444674

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ChAdOx1 nCoV-19
Description: Dose of 5-7.5x10\^10vp of ChAdOx1 nCoV-19

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ChAdOx1 nCoV-19
Description: Dose of 5-7.5x10\^10vp of ChAdOx1 nCoV-19

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ChAdOx1 nCoV-19
Description: Dose of 5-7.5x10\^10vp of ChAdOx1 nCoV-19

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ChAdOx1 nCoV-19
Description: Dose of 5-7.5x10\^10vp of ChAdOx1 nCoV-19

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Normal saline 0.9%
Description: Normal saline 0.9% as placebo
Study: NCT00700349

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Small loan
Description: Applicants in the treatment group were offered an interest rate, loan size, and maturity per the lender's standard underwriting criteria, involving a 4-month maturity at 11.75% per month, charged on the original balance (200% annual percentage rate).
Study: NCT04444674

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Normal saline 0.9%
Description: Normal saline 0.9% as placebo

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Normal saline 0.9%
Description: Normal saline 0.9% as placebo

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Normal saline 0.9%
Description: Normal saline 0.9% as placebo
Study: NCT00574392

Intervention type: DEVICE
Intervention: Multiwavelength and coherence confocal reflectance microscopy (Vivascope 1500m multiwavelength)
Description: Patients will be imaged with the Vivascope 1500m multiwavelength coherence microscope during a single patient visit. The lesion will be photographed with high resolution photography and surface epiluminescence microscopy. The clinically uninvolved site will be imaged in the same manner.
Study: NCT00236210

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Action Score
Description: Improvement in a novel 100-point score summarizing cardiovascular risk.
Study: NCT03772795

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Orthodontic Alignment
Description: Group 1:- Teeth alignment in this group started using round 0.014 NiTi arch wire. The 0.014 NiTi arch wire was placed into the slots of the brackets and tied with elastomers by figure of 8. During this stage, only tipping movement was applied.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Orthodontic Alignment
Description: Group 2: Teeth alignment using clear aligners.
Study: NCT02356523

Intervention type: DIAGNOSTIC_TEST
Intervention: Confusion Assessment Method
Description: Administration of Confusion Assessment Method at patent over 65 years at admission and every day until discharge

Intervention type: DIAGNOSTIC_TEST
Intervention: Confusion Assessment Method
Description: Administration of Confusion Assessment Method at patent over 65 years at admission and every day until discharge